FDA Withdraws Approval for 23 Generic Drug Applications
January 15, 2025
January 15, 2025
WASHINGTON, Jan. 15 (TNSFR) -- The Food and Drug Administration (FDA) has announced the withdrawal of approval for 23 abbreviated new drug applications (ANDAs) across a range of therapeutic categories.
The affected drugs include promethazine hydrochloride injectables by Teva Pharmaceuticals, ranitidine tablets by Strides Pharma, and fentanyl citrate tablets by Watson Laboratories, among others.
The withdrawals are effective February 14, 2025, following written notific . . .
The affected drugs include promethazine hydrochloride injectables by Teva Pharmaceuticals, ranitidine tablets by Strides Pharma, and fentanyl citrate tablets by Watson Laboratories, among others.
The withdrawals are effective February 14, 2025, following written notific . . .